October 16, 2026 01:30 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Aamir Khan’s nephew Imran Khan asked to leave India by Oct 28 after joining anti-CEC protest | ‘Their crime? Demanding justice’: Rahul Gandhi slams 4 AM detention of Ankita Bhandari’s parents | ‘Bangladesh showed us the way’: Neha Bora’s remarks spark BJP attack on Rahul Gandhi | Chingrighata flyover skid scare: Bikes fall, anti-skid blocks installed overnight as Bengal Minister Agnimitra Paul faces criticism | Meerut blue drum murder case: Muskaan, her lover get death sentence | 'Rise up, young patriots!': American singer Mary Millben alleges CJP gets US funding, urges peaceful protests | 'Won't go unchallenged': Muhammad Yunus heckling in New York triggers legal action warning | flydubai cockpit attack probe widens: Two Maldivian pilots detained in UAE over links to Omani co-pilot | Netflix scores big FIFA deal: All 104 World Cup 2030 matches to stream live in Spain, Andorra | Jantar Mantar crackdown: CJP's Saurav Das, Ashutosh Ranka sent to jail for 5 days
Black Fungal Disease | Amphotericin B

Centre asks drug manufacturers to increase production of amphotericin B to treat Black Fungus Disease

| @indiablooms | May 13, 2021, at 07:55 am

New Delhi/IBNS: The Central government has started working with the pharma companies producing amphotericin B to ramp up the production of anti-fungal medicine used in the treatment of mucormycosis, the “black fungus" infection being reported in some covid-19 patients across India.

“A sudden increase in demand has been observed in some states for amphotericin B which is being actively prescribed by the physicians to patients suffering from mucormycosis, a post-covid complication. The Government of India is therefore engaging with the manufacturers to ramp up production of the drug. The supply position is expected to improve with extra imports of this drug and increase in its production domestically," the department of pharmaceuticals said in a statement on Wednesday.

The department has reviewed the stock position and demand pattern for amphotericin B and allocated the drug to states and Union territories based on the estimated supply till May 31.

The Centre has also directed the states to set up a mechanism to ensure equitable distribution of the drug to all hospitals where covid-19 patients are undergoing treatment.

State have been also asked to spread information about the ‘point of contact’ for these hospitals from where they can obtain the drug from the state’s quota.

The supply of the amphotericin B drug will be monitored by the National Pharmaceuticals Pricing Authority (NPPA), the regulatory body responsible for drug price and availability, said the department..

According to data on NPPA’s website, Bharat Serums and Vaccine, Wockhardt, Abbott Healthcare, United Biotech and Cipla are some of the manufacturers of the drug.

Demand for amphotericin B has spiked in the last few weeks as more and more cases of mucormycosis were reported, which is a rare infection seen in some patients who are on medication for covid-19 or recovered from it.

According to experts, the rare infection caused by a group of moulds called "mucormycetes" and affect people with weak immune systems or having commorbidities or those who have been taking immunosupressants.

An ill patient may inhale the moulds present in the air which may then enter the sinus cavities, lungs, chest cavities and brain, causing complications.

Symptoms of the infection included headache, fever, pain under the eyes, nasal or sinus congestion and partial loss of vision. Facial deformity is a charecteristic feature when the disease spreads in the body.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.